Literature DB >> 12571063

Studies on the mode of action of reutericyclin.

Michael G Gänzle1, Rudi F Vogel.   

Abstract

The mode of action of reutericyclin was determined with fluorescent dyes that probed the permeability of the cytoplasmic membrane by large molecules, protons, and potassium. A comparison of reutericyclin activity with those of nisin, nigericin, and valinomycin demonstrated that reutericyclin does not form pores but selectively dissipates the transmembrane proton potential.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12571063      PMCID: PMC143594          DOI: 10.1128/AEM.69.2.1305-1307.2003

Source DB:  PubMed          Journal:  Appl Environ Microbiol        ISSN: 0099-2240            Impact factor:   4.792


  7 in total

1.  The First Low Molecular Weight Antibiotic from Lactic Acid Bacteria: Reutericyclin, a New Tetramic Acid.

Authors: 
Journal:  Angew Chem Int Ed Engl       Date:  2000-08-04       Impact factor: 15.336

Review 2.  Lantibiotics: structure, biosynthesis and mode of action.

Authors:  O McAuliffe; R P Ross; C Hill
Journal:  FEMS Microbiol Rev       Date:  2001-05       Impact factor: 16.408

3.  Interaction of the cyclic antimicrobial cationic peptide bactenecin with the outer and cytoplasmic membrane.

Authors:  M Wu; R E Hancock
Journal:  J Biol Chem       Date:  1999-01-01       Impact factor: 5.157

4.  Contribution of reutericyclin production to the stable persistence of Lactobacillus reuteri in an industrial sourdough fermentation.

Authors:  Michael G Gänzle; Rudi F Vogel
Journal:  Int J Food Microbiol       Date:  2003-01-15       Impact factor: 5.277

5.  Characterization of reutericyclin produced by Lactobacillus reuteri LTH2584.

Authors:  M G Gänzle; A Höltzel; J Walter; G Jung; W P Hammes
Journal:  Appl Environ Microbiol       Date:  2000-10       Impact factor: 4.792

6.  A Novel Method for Continuous Determination of the Intracellular pH in Bacteria with the Internally Conjugated Fluorescent Probe 5 (and 6-)-Carboxyfluorescein Succinimidyl Ester.

Authors:  P Breeuwer; J Drocourt; F M Rombouts; T Abee
Journal:  Appl Environ Microbiol       Date:  1996-01       Impact factor: 4.792

7.  Factors affecting antibacterial activity of hop compounds and their derivatives.

Authors:  W J Simpson; A R Smith
Journal:  J Appl Bacteriol       Date:  1992-04
  7 in total
  15 in total

1.  Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.

Authors:  Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Journal:  Antimicrob Agents Chemother       Date:  2005-03       Impact factor: 5.191

2.  Revisiting quorum sensing: Discovery of additional chemical and biological functions for 3-oxo-N-acylhomoserine lactones.

Authors:  Gunnar F Kaufmann; Rafaella Sartorio; Sang-Hyeup Lee; Claude J Rogers; Michael M Meijler; Jason A Moss; Bruce Clapham; Andrew P Brogan; Tobin J Dickerson; Kim D Janda
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-27       Impact factor: 11.205

3.  Effects of different probiotic strains B. lactis, L. rhamnosus and L. reuteri on brain-intestinal axis immunomodulation in an endotoxin-induced inflammation.

Authors:  Monique Michels; Gabriel Fernandes Alves Jesus; Mariane Rocha Abatti; Emily Córneo; Luana Cucker; Heloisa de Medeiros Borges; Natan da Silva Matos; Luana Bezerra Rocha; Rodrigo Dias; Carla Sasso Simon; Ana Paula Lorenzen Voytena; Marina Rossetto; Fernanda Ramlov; Felipe Dal-Pizzol
Journal:  Mol Neurobiol       Date:  2022-06-08       Impact factor: 5.682

4.  An ABC transporter of Streptococcus pneumoniae involved in susceptibility to vancoresmycin and bacitracin.

Authors:  Petra Becker; Regine Hakenbeck; Bernhard Henrich
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

5.  Anti-Clostridium difficile potential of tetramic acid derivatives from Pseudomonas aeruginosa quorum-sensing autoinducers.

Authors:  Chihiro Ueda; Kazuhiro Tateda; Manabu Horikawa; Soichiro Kimura; Yoshikazu Ishii; Kaoru Nomura; Kanako Yamada; Takashi Suematsu; Yasuhisa Inoue; Masaji Ishiguro; Shinichi Miyairi; Keizo Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  2009-11-16       Impact factor: 5.191

6.  Defining the mode of action of tetramic acid antibacterials derived from Pseudomonas aeruginosa quorum sensing signals.

Authors:  Colin A Lowery; Junguk Park; Christian Gloeckner; Michael M Meijler; Ryan S Mueller; Helena I Boshoff; Ricky L Ulrich; Clifton E Barry; Douglas H Bartlett; Vladimir V Kravchenko; Gunnar F Kaufmann; Kim D Janda
Journal:  J Am Chem Soc       Date:  2009-10-14       Impact factor: 15.419

7.  Glycerol monolaurate antibacterial activity in broth and biofilm cultures.

Authors:  Patrick M Schlievert; Marnie L Peterson
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

8.  (S)-Reutericyclin: Susceptibility Testing and In Vivo Effect on Murine Fecal Microbiome and Volatile Organic Compounds.

Authors:  Bernhard Kienesberger; Beate Obermüller; Georg Singer; Barbara Mittl; Reingard Grabherr; Sigrid Mayrhofer; Stefan Heinl; Vanessa Stadlbauer; Angela Horvath; Wolfram Miekisch; Patricia Fuchs; Ingeborg Klymiuk; Holger Till; Christoph Castellani
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

9.  Enterococcus faecalis inhibits superantigen toxic shock syndrome toxin-1-induced interleukin-8 from human vaginal epithelial cells through tetramic acids.

Authors:  Amanda J Brosnahan; Joseph A Merriman; Wilmara Salgado-Pabón; Bradley Ford; Patrick M Schlievert
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

Review 10.  Progress in the discovery of treatments for C. difficile infection: A clinical and medicinal chemistry review.

Authors:  Lissa S Tsutsumi; Yaw B Owusu; Julian G Hurdle; Dianqing Sun
Journal:  Curr Top Med Chem       Date:  2014       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.